Photodynamic therapy for high-grade dysplasia in Barrett's oesophagus
National Institute for Clinical Excellence
Record ID 32004000782
English
Authors' objectives:
This study aims to assess the current evidence on the safety and efficacy of photodynamic therapy for high-grade dysplasia in Barrett's oesophagus.
Authors' recommendations:
Guidance 1.1 Current evidence on the safety of photodynamic therapy for high-grade dysplasia in Barrett's oesophagus appears adequate to support the use of this procedure. Photodynamic therapy appears efficacious in downgrading dysplasia in Barrett's oesophagus, when used for the treatment of high-grade dysplasia (a premalignant lesion). However, its efficacy in preventing the progression of Barretts oesophagus to invasive cancer is not clear.
1.2 Clinicians wishing to undertake photodynamic therapy for high-grade dysplasia in Barrett's oesophagus should take the following actions. - Inform the clinical governance leads in their Trusts. - Inform patients, as part of the consent process, about the uncertainty of influencing their long-term prognosis and provide them with clear written information. Use of the Institute's Information for the Public is recommended. - Audit and review clinical outcomes of all patients having photodynamic therapy for high-grade dysplasia in Barrett's oesophagus.
1.3 Publication of long-term efficacy outcomes will be useful in reducing the current uncertainty. Randomised trials are in progress and clinicians are encouraged to consider entering patients into these (www.cancerhelp.org.uk/trials/trials/default.asp). The Institute may review the procedure upon publication of further evidence.
1.4 This guidance is limited to the procedure using pharmaceuticals licensed for photodynamic therapy of oesophageal dysplasia.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cms/ip/ipcat.aspx?c=82716
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Barrett Esophagus
- Esophageal Neoplasms
- Photochemotherapy
- Precancerous Conditions
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.